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Three monoclonal antibodies have been produced that are specific for the activation peptide region in hu- 
man protein C. These antibodies inhibited the activation of protein C by thrombin and by the thrombin- 
thrombomodulin complex. A fourth monoclonal antibody specifically recognized the Ca2+-stabilized con- 
formation in protein C. This antibody bound both intact protein C and protein C from which the y-carboxy- 
glutamic acid-containing region had been removed by limited proteolysis. These results indicate that this 
antibody recognizes the conformation in protein C stabilized by Ca*+ bound to the single binding site that 
is independent of y-carboxyglutamic acid. 
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1. INTRODUCTION 
Protein C is a vitamin K-dependent glycoprotein 
that has been purified from bovine and human 
plasma [l-3]. It is a zymogen of a serine protease 
[4,5] and is rapidly activated by thrombin in com- 
plex with thrombomodulin, an endothelial cell 
cofactor [6-S]. Activated protein C degrades 
coagulation factors V, and VIII, by limited pro- 
teolysis [g-11]. After degradation, factor V, does 
not bind factor X,, nor does it interact with pro- 
thrombin, the substrate for factor Xa [ 12,131. This 
anticoagulant function of protein C requires pro- 
tein S, another vitamin K-dependent protein, as a 
cofactor [ 14,151. In vivo protein C is an important 
regulator of blood coagulation, as shown by the 
association of protein C deficiency with early 
adulthood venous thrombosis [ 16,171. 
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Protein C contains the vitamin K-dependent y- 
carboxyglutamic acid (Gla) residues that are re- 
quired for its Ca 2+-binding and biological activity 
[ 1,18,19]. In addition to the Gla residues, protein 
C has one residue of erythro-fl-hydroxyaspartic 
acid, a residue formed by postribosomal hydrox- 
ylation of aspartic acid [20]. The function of this 
modified amino acid is not known. Recently it was 
demonstrated that protein C, lacking the Gla 
region, still has one high affinity Ca2+-binding site 
[19,21]. Ca2+-binding to the Gla independent site 
induces a conformational change in protein C 
[21,22]. We have now made a monoclonal an- 
tibody againsts an epitope on human protein C 
which is expressed only in the presence of Ca2+. In 
the course of this work we also obtained antibodies 
against the activation peptide region of protein C, 
suggesting that this is a very immunogenic part of 
the protein. Here we describe some of the proper- 
ties of the monoclonal. antibody recognizing the 
Ca’+-induced conformation of protein C and of 
antibodies directed against the activation peptide 
region. 
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2. MATERIALS AND METHODS 
Keyhole limpet hemocyanin (KLH) and 
2,2’-azido-di(3-ethylbenzethiazoline)sulfonic acid 
(ABTS) was obtained from Sigma. Affigel 10 and 
nitrocellulose papers were from Biorad, DEAE- 
Sephacel from Pharmacia and maleidobenzoyl-N- 
hydroxysuccinimide ster (MBS) from Pierce. The 
p-nitroanilide substrate S-2238 was obtained from 
Kabi. The peptide Asp-Pro-Glu-Asp-Gln-Glu-Asp- 
Gln-Val-Asp-Pro-Arg-Leu-Ile-Asp-Cys was ob- 
tained from Peninsula and coupled to KLH as 
described by Liu et al. [23,24]. Horseradish peroxi- 
dase (HRP)-conjugated swine antirabbit immuno- 
globulin and HRP-conjugated rabbit antimouse 
immunoglobulin were obtained from Dako. 
Human protein C was purified and activated as 
described [lo]. Thrombomodulin was a gift from 
Drs Charles and Naomi Esmon. Bovine thrombin 
was obtained from prothrombin by activation with 
the venom from Oxyuris scutellatus scutellatus 
(Sigma) and purified as described by Owen and 
Jackson [25]. 
2.1. Production of monoclonal antibodies 
Mice were immunized with 1Opg of purified 
human protein C, emulsified in Freund’s complete 
adjuvant. The immunization was repeated after 1 
and 3 weeks, the last following emulsification in 
incomplete Freund’s adjuvant. The mouse with the 
highest antibody titer was selected, and boosted in- 
traperitoneally with 200 pg of human protein C on 
three consecutive days prior to cell fusion. Cell fu- 
sion and production of monoclonal antibodies was 
performed according to the procedure of Kohler 
and Milstein with the modifications described 
previously [26,27]. SP 2/O-Ag 14 or P3-NSl-1 
Ag 4 myeloma cells were used for the fusion. 
Positive clones were subcloned two or three times 
by limiting dilution, then expanded and injected 
intraperitoneally into pristine-primed Balb/c mice. 
After lo-12 days the mice were sacrificed, and the 
monoclonal antibodies were isolated from the 
ascites fluid by standard procedures; i.e. am- 
monium sulfate precipitation followed by ion ex- 
change chromatography on DEAE-Sepharose CL 
6B. 
2.2. Antigen binding assay 
Antibody-producing hybridomas were tested by 
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an enzyme-linked immunoadsorbent assay in 
96-well Dynatec or Linboro microtiter plates as 
described previously [27]. The plates were coated 
with human protein C, or with the synthetic pep- 
tide coupled to KLH or with KLH alone. HRP- 
conjugated rabbit antimouse immunoglobulins 
were used as a second antibody, with ABTS as a 
substrate. 
Clones specific for the Ca*+-induced conforma- 
tion of protein C were identified by a solid-phase 
radioimmunoassay essentially as described by 
Lewis et al. [28]. ‘Removeastrip’ microtiter plates 
(Dynatec) were coated at 4°C overnight with 50 ~1 
affinity-purified rabbit antimouse immuno- 
globulin (20pg/ml). After washing with 50 mM 
Tris-HCl, 0.15 M NaCl, pH 7.4, the plates were in- 
cubated for 15 min with 100 ~1 buffer containing 
bovine serum albumin (BSA) (10 mg/ml). In the 
test 40~1 of hybridoma supernatant was added to 
each well, followed by incubation at ambient 
temperature for 60 min. Next, using the same 
buffer, the plates were washed with 2 mM CaCl2 or 
2 mM EDTA, and then incubated at 4°C overnight 
with 5000 cpm (50 ~1) per well of ‘*‘I-labelled pro- 
tein C. After extensive washing, radioactivity was 
measured, and the amount of ‘*?-protein C bound 
in Ca*+ and EDTA-containing buffer compared. 
Rabbit antisera against protein C were tested by 
ELISA as described above using plates coated with 
either protein C, KLH-coupled peptide or KLH 
alone. In this case horseradish peroxidase- 
conjugated goat antirabbit antibodies were used. 
2.3. Electrophoretic and immunochemical 
procedures 
SDS-polyacrylamide slab gel electrophoresis was 
performed in lo-15% gradient gels [29,30]. Gels 
were either stained with Coomassie brilliant blue 
or subjected to Western blotting [31], with transfer 
of the proteins to nitrocellulose paper. Unoccupied 
protein sites were quenched with 5% teleostean 
liquid gelatin in 20 mM Tris, pH 7.4, 0.9% NaCl 
[32]. Subsequent antibody incubations were per- 
formed in this buffer and washes were made using 
the same buffer without gelatin. Transferred pro- 
teins were probed with either mouse monoclonal or 
rabbit antiserum against protein C. When 
monoclonal antibodies were used, the blots were 
overlayed with rabbit antiserum against mouse im- 
munoglobulins prior to addition of the labelled an- 
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tibody. The protein bands were visualized with 
horseradish peroxidase coupled to an affinity- 
purified goat antibody against rabbit immuno- 
globulins and using 3-amino-9-ethylcarbazole 
(20 mg in 2 ml dimethylformamide in 50 ml 50 M 
acetate buffer, pH 5.0, containing 20/l 30% 
HzOz) as a substrate. 
2.4. Inhibition of protein C activation by 
monoclonal antibodies 
When thrombin-thrombomodulin was used in 
the activation of purified human protein C, 50~1 
(3.7 pug) was mixed with antibody (11 ~1, 9.9 pg) in 
20 mM Tris-HCl containing 100 mM NaCl, pH 
7.4, and supplemented with 1% BSA and 5 mM 
CaC12. When thrombin alone was used in the ac- 
tivation the buffer contained 5 mM EDTA instead 
of CaC12. After 60 min incubation in 1 ml Eppen- 
dorf vials at 37”C, 50~1 of the mixture was 
transferred to a second vial and then either 10 ,ul of 
thrombin (10 U/ml) and 10 ~1 of buffer, or a mix- 
ture of lop1 of thrombin (1 U/ml) and 10 pl of 
thrombomodulin (1.78 pug/ml) were added. After 
incubation for 60 min at 37”C, the thrombin ac- 
tivity was inhibited by the addition of 10~1 an- 
tithrombin III (1.43 mg/ml). Next, 50~1 of the 
reaction mixture was transferred to a 1 ml cuvette 
containing 850 pl buffer and 100~1 of S-2238 
(2 mM), and finally, the protein C amidiolytic ac- 
tivity was measured from the increase in absor- 
bance at 405 nm. Activated or unactivated protein 
C, mixed with an unrelated monoclonal antibody 
was used in control experiments. 
2.5. Immobilization of monoclonal antibodies 
The Ca2+-dependent antibody, HPC4, in 0.1 M 
morpholinopropane sulfonic acid buffer, pH 7.0, 
was coupled to Affigel 10 (5.5 mg antibody per ml 
gel) according to the manufacturer’s instructions. 
2.6. Determination of binding constant of the 
monoclonai antibodies 
The binding constants were determined from 
measurement of the competition between unla- 
belled protein C and 1251-labelled protein C for 
binding to the monoclonal antibodies in a double 
antibody radioimmunoassay. The data were 
evaluated with the aid of Scatchard plots [33]. 
3. RESULTS AND DISCUSSION 
The tissue culture supernatants obtained from 
spleen cells from immunized mice were fused with 
myeloma cells and were tested with the objective of 
obtaining monoclonal antibodies against the ac- 
tivation peptide region of protein C and antibodies 
that specifically recognized the Ca’+-dependent 
conformation of protein C. After cloning three 
times, 3 antiactivation peptide antibodies (HPC 1, 
5 and 9) and the antibody with the most pro- 
nounced Ca2+ dependence (HPC 4) were grown as 
ascitic tumours. The monoclonal antibodies were 
purified by ammonium sulfate precipitation and 
DEAE-cellulose chromatography. HPC 1, 5 and 9 
from different master wells had different 
mobilities on agarose gel electrophoresis and were 
thus unrelated. The properties of the monoclonal 
antibodies are summarized in table 1. The purified 
antibodies were tested by solid phase immunoassay 
with microtiter plates coated with protein C and 
plates coated with the synthetic peptide. HPC 1 
reacted with both the intact protein and the syn- 
thetic peptide but not the carrier protein (KLH) 
(fig.1). In addition, it did not react with activated 
protein C (not shown). HPC 5 and 9 had the same 
specificity. On the contrary, HPC 4 did not react 
with the synthetic peptide. These results indicate 
that the activation peptide region in protein C is 
immunogenic, and this is corroborated by the 
finding that a rabbit antiserum against protein C 
also reacts with the synthetic peptide (fig.1). The 
specificity of the monoclonal antibodies was also 
tested in immunoblotting experiments (fig.2). 
HPC 1 recognized the zymogen but not activated 
protein C. Likewise it recognized the heavy chain 
Table 1 
Properties of monoclonal antibodies against human 
protein C 
Clone Cell line IgG samples Epitope Binding 
constant 
@I-‘) 
HPC 1 SP2-0 IgGl x Act peptide 3 x 10s 
HPC 4 NS-1 IgGl x Ca’+- 
dependent 1 x lo9 
HPC 5 SP2-0 IgGl x Act peptide 1 x lo9 
HPC 9 SP2-0 IgG2a x Act peptide 1 x IO9 
77 
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Antlbody concentration (mg/ml) 
F 1 I I I 
HpC-4 
0 LI I I I I I 
1o-5 1O-4 1o-3 lo-’ 10-l 
Antibody concentration (mg/ml) 
E 0.6 
C 
F ’ I I I _I 
Polyclonal 
0 L ’ I I I I 
1o-4 1o-3 lo+ 10-l 
Antiserum dilution 
Fig. 1. Antigenic specificity of monoclonal antibodies as 
evaluated by ELISA assay. The microliter plates were 
coated with protein C (A---A), synthetic peptide (see 
section 2) coupled to KLH (H) or with KLH only 
(M). 
of the unactivated protein but not of the activated 
protein. The antibodies HPC 5 and HPC 9 had the 
same specificity. 
The antibodies specific for the Ca’+-induced 
conformation in protein C were tested by solid 
phase radioimmunoassay. Measurements were 
made of the binding of 1251-labelled protein C to 
microtiter plates previously coated with affinity- 
purified rabbit antimouse immunoglobulins. The 
binding of the radiolabelled tracer in Ca*+ and 
EDTA containing buffer was compared (fig.3). 
The binding of protein C to the antibodies directed 
against the activation peptide region was not in- 
fluenced by the presence of Ca*+. In contrast, 
HPC 4 bound protein C with high affinity in the 
presence of Ca*+, but only weakly in the presence 
of EDTA. In immunoblotting experiments, HPC 4 
reacted with both the zymogen and the active en- 
zyme prior to reduction of disulfide bridges but did 
not recognize the electrophoretically separated 
light and heavy chains (fig.2). 
The ability of the monoclonal antibodies to in- 
hibit the activation of protein C was investigated. 
Thrombin was used for the activation both alone 
in EDTA-containing buffer and in complex with 
thrombomodulin in Ca*+-containing buffer. As 
seen in fig.4, activated protein C had a slightly 
higher amidolytic activity in the presence of Ca*+ 
than in EDTA-containing buffer [34]. The three 
monoclonal antibodies against the activation pep- 
0 
1 2 3 4 1234 1 234 
Fig.2. Immunoblotting with rabbit antiserum against 
protein C (A), monoclonal antibody HPC 1 (B) and 
monoclonal antibody HPC 4 (C). Lanes 1 and 2, 
unreduced samples; lanes 3 and 4, samples reduced with 
,&-mercaptoethanol. Lanes 1 and 3, protein C; lanes 2 
and 4, activated protein C. 
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rlpc-1 HpC-4 HpC-5 HpC-9 
Fig.3. Binding of tz51-protein C to monoclonal 
antibodies from ascites fluid as determined by solid 
phase radioimmunoassay. The assay was performed in 
Ca2+-containing buffer (filled bars) or in EDTA- 
containing buffer (open bars). The binding in the 
Ca’+-containing buffer was arbitrarily assigned a value 
of 100% in each experiment. Blank figures did not 
exceed 15% of the monoclonal binding in the 
Ca2+-containing buffer. 
tide region inhibited the activation of protein C 
both by thrombin and by thrombin-thrombo- 
modulin. On the other hand, HPC 4 did not inhibit 
the activation of protein C by the thrombin- 
thrombomodulin complex. 
Protein C from which the Gla-region had been 
removed by limited proteolysis with chymotrypsin 
still bound one Ca2+ with high affinity. Binding of 
this single Ca2+ induced an easily monitored con- 
formational change in the protein [21,22]. Gla- 
domainless protein C was prepared as described by 
Esmon et al. [19] characterized by SDS- 
polyacrylamide gel electrophoresis and its binding 
to HPC 4 studied. Protein C, activated protein C 
and Gla-domainless protein C all bound to a col- 
umn with immobilized HPC 4 in the presence of 
Ca2+ and could then be eluted with EDTA- 
containing buffer (fig.5). HPC 4 thus recognized 
the conformational change induced in protein C by 
the Gla-independent Ca2+ binding site. 
We have previously noted that the activation 
peptide region in bovine protein C is very im- 
munogenic [27]. The synthetic peptide corre- 
sponding to residues 1 to 15 in the heavy chain of 
human protein C that we have used was synthe- 
sized with a proline residue in position 2 [2]. More 
recent reports have found a threonine residual in 




HpC-1 I C-4 HpC-5 HpC-9 
Fig.4. Effect of monoclonal antibodies on activation of 
protein C. Protein C was incubated with antibodies and 
activated with either thrombin alone in EDTA- 
containing buffer (open bars) or with the thrombin- 
thrombomodulin complex in Ca2+-containing buffer 
(filled bars). Activated protein C was measured with 
S-2238 as described in section 2. CA, activated protein C 
alone. 
C [35,36]. There may thus be additional clones 
producing antibodies directed against the activa- 
tion peptide in protein C that were not detected 
with our screening procedure. The activation pep- 
tide has 7 charged amino acids and should thus be 
very immunogenic as predicted by the method of 
Hopps and Wood [37]. Recently Suzuki et al. 
characterized 13 monoclonal antibodies against 
human protein C [38]. In this case however none 
was directed against the activation peptide region. 
The reason for this is unknow, but it may be due 
to different immunization procedures. 
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